Similar articles

• Promoter attenuation in gene therapy: interferon-gamma and tumor necrosis factor-alpha inhibit transgene expression.

  Qin L, Ding Y, Pahud DR, Chang E, Imperiale MJ, Bromberg JS. Qin L, et al. Hum Gene Ther. 1997 Nov 20;8(17):2019-29. doi: 10.1089/hum.1997.8.17-2019. Hum Gene Ther. 1997. PMID: 9414251
• Interactions between the immune system and gene therapy vectors: bidirectional regulation of response and expression.

  Bromberg JS, Debruyne LA, Qin L. Bromberg JS, et al. Adv Immunol. 1998;69:353-409. Adv Immunol. 1998. PMID: 9646848 Review. No abstract available.
• Picolinic acid- or desferrioxamine-inducible autocrine activation of macrophages engineered to produce IFNgamma: an approach for gene therapy.

  Pastorino S, Carta L, Puppo M, Melillo G, Bosco MC, Varesio L. Pastorino S, et al. Gene Ther. 2004 Mar;11(6):560-8. doi: 10.1038/sj.gt.3302217. Gene Ther. 2004. PMID: 14961065
• Stimulatory and inhibitory action of cytokines on the regulation of hCMV-IE promoter activity in human endothelial cells.

  Ritter T, Brandt C, Prösch S, Vergopoulos A, Vogt K, Kolls J, Volk HD. Ritter T, et al. Cytokine. 2000 Aug;12(8):1163-70. doi: 10.1006/cyto.2000.0689. Cytokine. 2000. PMID: 10930292
• Adaptive and innate immune responses to gene transfer vectors: role of cytokines and chemokines in vector function.

  Chen D, Murphy B, Sung R, Bromberg JS. Chen D, et al. Gene Ther. 2003 Jun;10(11):991-8. doi: 10.1038/sj.gt.3302031. Gene Ther. 2003. PMID: 12756420 Review. No abstract available.